Olon France is a leading contract development and manufacturing organization (CDMO) with over 25 years of expertise in process development and both non-GMP and GMP production of antibodies, proteins, and bioconjugates. Utilizing advanced mammalian and microbial expression platforms, we deliver fully tailored solutions for a broad spectrum of biologics—including complex, hard-to-express molecules such as bispecific antibodies and antibody-drug conjugates (ADCs).
Founded in 2000, Olon France offers end-to-end integrated services—from early R&D through clinical-grade drug substance (DS) and drug product (DP) manufacturing—to support biopharma partners at every development stage. As part of the privately owned Olon Group, a global leader in active pharmaceutical ingredient (API) CDMO and generics, we benefit from a proven network of 14 manufacturing sites, 9 R&D centers, and 2,800 employees worldwide, including over 350 dedicated R&D scientists.
Backed by Olon Group’s €615 million in revenues (2024) and its recognized leadership in both chemical and biological technologies, Olon France is the partner of choice for advancing innovative therapies to market under the highest standards of safety, quality, and environmental stewardship.
